Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.00
Bid: 63.00
Ask: 65.00
Change: -0.50 (-0.78%)
Spread: 2.00 (3.175%)
Open: 64.50
High: 64.50
Low: 64.00
Prev. Close: 64.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDS Biotech: Submission of Phase 3 Protocol to FDA

14 Aug 2023 17:51

RNS Number : 2820J
NetScientific PLC
14 August 2023
 

RNS: For immediate release

NetScientific plc

PDS Biotechnology Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial

VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA® in recurrent or metastatic HPV16-positive head and neck cancer

PDS Biotech anticipates initiating the VERSATILE-003 trial in the fourth quarter of 2023

NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, reports that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on its proprietary T cell activating platforms, has announced the submission to the U.S. Food and Drug Administration (FDA) of an updated Chemistry, Manufacturing and Controls (CMC) package and a Phase 3 multicenter registrational protocol to the company's Investigational New Drug (IND) submission to evaluate the combination of PDS0101 and KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of recurrent or metastatic human papillomavirus (HPV) 16-positive head and neck squamous cell carcinoma (HNSCC). The protocol was developed in accordance with guidance from the FDA on key elements of the Phase 3 program to support the eventual submission of a Biologics License Application (BLA).

The Phase 3 trial, named VERSATILE-003, is a randomized, active comparator-controlled study designed to investigate the safety and efficacy of PDS0101 combined with KEYTRUDA® compared to KEYTRUDA® monotherapy in immune checkpoint inhibitor (ICI)-naïve patients with recurrent or metastatic HPV16-positive HNSCC. The primary efficacy endpoint for VERSATILE-003, per the protocol, is overall survival (OS). The Phase 3 study is expected to involve approximately 90-100 clinical sites globally. PDS Biotech anticipates initiating the VERSATILE-003 Phase 3 trial in the fourth quarter of 2023.

Dr Ilian Iliev, CEO of NetScientific, commented:

"We congratulate PDS Biotech on reaching this significant milestone and look forward to seeing the initiation in Q4 2023 of this important Phase 3 trial, VERSATILE-003."

Dr Lauren V. Wood, PDS Biotech's Chief Medical Officer, said:

"Submission of the protocol and supportive CMC documents for this Phase 3 registrational trial is an important milestone for PDS Biotech and our VERSATILE-003 program investigating PDS0101 in combination with KEYTRUDA® as a potential treatment for recurrent or metastatic HPV16-positive HNSCC. Interim data from our ongoing VERSATILE-002 Phase 2 clinical trial have been very encouraging, with impressive interim OS and PFS results. With VERSATILE-003, we have an opportunity to confirm the Phase 2 results from VERSATILE-002 in a controlled, Phase 3 clinical trial comparing the combination of PDS0101 and KEYTRUDA® to KEYTRUDA® monotherapy."

A full version of PDS Biotech's announcement can be accessed here:

https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/125-2023-news/854-iotechnnouncesubmissionofhase3rotocolto20230814

-Ends- 

For more information, please contact:

 

NetScientific

Ilian Iliev, CEO Via Belvedere Communications

 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel +44 (0)20 7220 1666

 

Belvedere Communications

John West / Llew Angus +44 (0) 203 008 6867

Email: nsci@belvederepr.com

 

About NetScientific

NetScientific plc (AIM: NSCI) is a deep tech and life sciences VC investment group with an international portfolio of innovative companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

 

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune®, Versamune® plus PDS0301, and Infectimune® T cell-activating platforms. We believe our targeted immunotherapies have the potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the ability to reduce and shrink tumours and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers in multiple Phase 2 clinical trials and will be advancing into a Phase 3 clinical trial in combination with KEYTRUDA® for the treatment of recurrent/metastatic HPV16-positive head and neck cancer in 2023. Our Infectimune® based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURKZGMRVDGGFZM
Date   Source Headline
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension
9th Nov 20227:00 amRNSBoard Change
7th Nov 20223:40 pmRNSPDS reports presentation of data at cancer society
20th Oct 20227:00 amRNSEMV Capital secures investment in Ventive
11th Oct 20224:00 pmRNSPDS Update
3rd Oct 20221:56 pmRNSPDS completes End-of-Phase 2 meeting with FDA
30th Sep 20227:00 amRNSHalf-year Report
25th Aug 20227:00 amRNSPDS Completes $35 Million Financing Agreement
16th Aug 20227:00 amRNSAcquisition of 30% Vortex stake & new Vortex CEO
8th Aug 20224:45 pmRNSPDS Reports Q2 2022 Results & Business Update
29th Jun 20222:05 pmRNSResult of AGM
28th Jun 20229:15 amRNSHolding(s) in Company
27th Jun 20228:30 amRNSDirector/PDMR Shareholding
27th Jun 20228:30 amRNSHolding(s) in Company
22nd Jun 20227:00 amRNSResult of Placing and Total Voting Rights
21st Jun 20224:41 pmRNSProposed Placing to raise at least £1.5 million
17th Jun 202212:00 pmRNSNetScientific to increase Q-Bot stake to 23.7%
15th Jun 20227:00 amRNSQ-Bot secures £1.6m of investment to fund growth
7th Jun 202211:07 amRNSNotice of AGM and Annual Report & Accounts
6th Jun 20227:00 amRNSPDS Granted FDA Fast Track Designation for PDS0101
27th May 20222:39 pmRNSPDS Biotech - new data for ongoing clinical trials
19th May 20227:00 amRNSGeneral Counsel Strategic Hire & Grant of Options
16th May 20227:00 amRNSProAxsis Update
12th May 20227:00 amRNSFinal Results
11th May 20223:46 pmRNSPDS Reports Q1 2022 Results & Business Update
9th May 20227:00 amRNSNotice of Results & Investor Presentation
6th May 20227:00 amRNSAcquisition of 30% of Vortex Biotech Holdings
25th Apr 20222:05 pmRNSSecond Price Monitoring Extn
25th Apr 20222:00 pmRNSPrice Monitoring Extension
25th Apr 202211:05 amRNSSecond Price Monitoring Extn
25th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 20221:24 pmRNSPDS Provides Business Update & Full-Year Results
4th Mar 20227:30 amRNSPublication of Shareholder Newsletter
24th Feb 20224:45 pmRNSPDS Announces Preliminary Safety Data on PDS0101
15th Feb 20222:32 pmRNSPDS Clinical Trial with Mayo Clinic
2nd Feb 20223:00 pmRNSPDS Phase 2 Trial Update
28th Jan 20228:45 amRNSPDS Announces Preclinical Data for PDS0202 Vaccine
18th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20222:20 pmRNSPDS Granted Novel HPV16 Immunotherapy Patent
10th Jan 20227:00 amRNSProAxsis CEO End of Year Update
29th Dec 20218:47 amRNSIssue of Equity
21st Dec 20211:59 pmRNSTR-1: Form for notification of major holdings
21st Dec 20217:00 amRNSQ-Bot Investment and Share Acquisition
20th Dec 20217:00 amRNSAcquisition of majority stake in Cetromed
13th Dec 20217:00 amRNSMartlet Capital Update
6th Dec 20212:53 pmRNSPDS Phase 2 Clinical Trial Update
26th Nov 20217:00 amRNS$1million investment in portfolio company, EpiBone
10th Nov 20211:58 pmRNSPDS Reports Q3 2021 Results & Business Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.